A new study suggests that a course of the drug doxycycline can decrease acute seizure-related hospitalization and deaths related to nodding syndrome.
FDA approves AChEI ALPHA-1062 for Alzheimer’s disease treatment
On July 29, 2024, the U.S. FDA approved Alpha Cognition Inc.’s ALPHA-1062 (Zunveyl®), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer’s disease.
August 5, 2024